PARP inhibitors to treat BRCA defects?


Question from PondsG: PARP inhibitors are being tested for efficacy against BRCA1 and 2 defects in breast and ovarian cancers. Is there any indication as to whether such treatments are likely to benefit both types? Is there any hope for a recurrence-preventive trial for those affected?
Answers - Carol Kaplan PARP inhibitors are drugs intended to target specifically the BRCA mutation carrier population. We happen to have an open clinical trial at the University of Pennsylvania that is currently enrolling breast cancer patients with metastatic disease. There has already been reported promising data for PARP inhibitor therapy for the treatment of ovarian cancer, fortunately. And preliminary clinical data in the breast cancer population suggests that this therapy could be worthwhile.

On Wednesday, June 18, 2008 our Ask-the-Expert Online Conference was called Updates from the 2008 ASCO Annual MeetingGenerosa Grana, M.D., F.A.C.P. and Carol Kaplan, M.D. answered your questions about the latest research advances on screening, treatment, side effects, and more.

The materials presented in these conferences do not necessarily reflect the views of Breastcancer.org. A qualified healthcare professional should be consulted before using any therapeutic product or regimen discussed. All readers should verify all information and data before employing any therapies described here.

A production of LiveWorld, Inc.
Copyright 2010. All rights reserved.

Was this resource helpful?

Yes No
Evergreen-donate
Back to Top